



Senegal

African Region



I. Epidemiological profile

Population (UN Population Division)	2017	%
High transmission (>1 case per 1000 population)	15.8M	99
Low transmission (0-1 case per 1000 population)	91.5K	1
Malaria free (0 cases)	0	-
Total	15.9M	

Parasites and vectors			
Major plasmodium species:	P.falciparum: 100 (%) , Pvivax: 0 (%)		
Major anopheles species:	<i>An. gambiae</i> , <i>An. arabiensis</i> , <i>An. funestus</i> , <i>An. pharoensis</i> , <i>An. melas</i>		
Reported confirmed cases (health facility)*:	395 706	Estimated cases:	1M [700.8K, 1.4M]
Confirmed cases at community level:	126 026		
Confirmed cases from private sector:	-		
Reported deaths:	284	Estimated deaths:	4.5K [4.1K, 5K]

* Includes cases from the community and the private sector

II. Intervention policies and strategies

Intervention	Policies/Strategies	Yes/No	Year adopted
ITN	ITNs/LLINs distributed free of charge	Yes	2009
	ITNs/LLINs distributed to all age groups	Yes	2005
IRS	IRS is recommended	Yes	2005
	DDT is used for IRS	No	-
Larval control	Use of Larval Control	No	-
IPT	IPT used to prevent malaria during pregnancy	Yes	2005
Diagnosis	Patients of all ages should receive diagnostic test	Yes	2007
	Malaria diagnosis is free of charge in the public sector	Yes	2007
Treatment	ACT is free for all ages in public sector	Yes	2010
	The sale of oral artemisinin-based monotherapies (oAMTs) has never been allowed.		2007
	Single dose of primaquine (0.25 mg base/kg) is used as gametocidal medicine for P. falciparum	Yes	2017
	Primaquine is used for radical treatment of P. vivax	No	-
	G6PD test is a requirement before treatment with primaquine	No	-
	Directly observed treatment with primaquine is undertaken	Yes	2017
	System for monitoring of adverse reaction to antimalarials exists	Yes	2006
	Surveillance	ACD for case investigation (reactive)	Yes
	ACD at community level of febrile cases (pro-active)	Yes	2013
	Mass screening is undertaken	No	-
	Uncomplicated P. falciparum cases routinely admitted	Yes	2006
	Uncomplicated P. vivax cases routinely admitted	No	-
	Case and foci investigation undertaken	Yes	2012
	Case reporting from private sector is mandatory	No	-

Antimalaria treatment policy	Medicine	Year adopted
First-line treatment of unconfirmed malaria	AL; AS+AQ; DHA-PPQ	2005
First-line treatment of P. falciparum	AL; AS+AQ; DHA-PPQ	2005
For treatment failure of P. falciparum	-	-
Treatment of severe malaria	AS; QN	2005
Treatment of P. vivax	-	-
Dosage of primaquine for radical treatment of P. vivax		
Type of RDT used	Pf only	

Therapeutic efficacy tests (clinical and parasitological failure, %)							
Medicine	Year	Min	Median	Max	Follow-up	No. of studies	Species
AL	2010-2014	0	0	1.6	28 days	5	<i>P. falciparum</i>
AS+AQ	2010-2014	0	0.5	1.7	28 days	3	<i>P. falciparum</i>
DHA-PPQ	2010-2014	0	0	0.9	42 days	3	<i>P. falciparum</i>

Resistance status by insecticide class (2010-2017) and use of class for malaria vector control (2017)				
Insecticide class	Years	(%) sites ¹	Vectors ²	Used ³
Carbamates	2010-2017	51.02% (49)	<i>An. arabiensis</i> , <i>An. gambiae</i> s.L., <i>An. gambiae</i> s.s.	No
	2010-2017	96.08% (51)	<i>An. arabiensis</i> , <i>An. funestus</i> s.L., <i>An. gambiae</i> s.L., <i>An. gambiae</i> s.s.	No
Organophosphates	2010-2017	15.69% (51)	<i>An. arabiensis</i> , <i>An. gambiae</i> s.L., <i>An. gambiae</i> s.s.	Yes
	2010-2017	81.13% (53)	<i>An. arabiensis</i> , <i>An. funestus</i> s.L., <i>An. gambiae</i> s.L., <i>An. gambiae</i> s.s.	Yes


¹Percent of sites for which resistance confirmed and total number of sites that reported data (n)

²Principal vectors that exhibited resistance


³Class used for malaria vector control in 2017

III. Charts

Sources of financing




Government expenditure by intervention in 2017




IV. Coverage

Coverage of ITN and IRS



Cases tested and treated in public sector




Source: DHS 2005, 2011, 2013, 2014, 2015, 2016, MIS 2006, 2009


Source: DHS 2011, 2013, 2014, 2015, 2016, MIS 2006, 2009

V. Impact

Cases treated




Test positivity



Source: DHS 2005, 2011, 2013, 2014, 2015, 2016, MIS 2006, 2009

V. Impact

Confirmed malaria cases per 1000 and ABER



Malaria admissions and deaths

